Your browser doesn't support javascript.
loading
Screening of PPAR-γ Agonist Active Ingredient of Flavonoids from Artemisia ordosica by Molecular Docking Technology / 中国药房
China Pharmacy ; (12): 58-62, 2018.
Artigo em Chinês | WPRIM | ID: wpr-704519
ABSTRACT

OBJECTIVE:

To screen the agonist active ingredients of peroxisome proliferator-activated receptor-γ (PPAR-γ) in flavonoids from Artemisia ordosica,and provide reference for finding antidiabetic agents in A.ordosica.

METHODS:

Using known PPAR-γagonist rosiglitazone as positive control,molecular docking technology was conducted for docking one by one for 18 flavonoids and PPAR-7 targets obtained from A.ordosica.It was compared with binding affinities and binding modes of compounds and PPAR-7 targets,and the possible PPAR-γ agonist ingredients in A.ordosica were screened.

RESULTS:

5 flavonoids showed good docking affinities,in which,compound 3 (5,3',4'-trihydroxy-7-methoxyflavone) showed the highest (-8.3 kcal/mol).Docking mode analysis showed that the phenol oxygen on ring A and ring B of the flavonoids with LBD active site of PPAR-γ formed one (Tyr327) or two hydrogen bonding (Tyr327,Arg288),which played an important role in the binding of flavonoids and PPAR-γ and the stability of PPAR-γ conformation.

CONCLUSIONS:

Results of virtual screening in molecular docking technology indicate that flavonoids (mostly containing multiple free phenolic hydroxyl groups) in can easily form good docking mode and high affinity with PPAR-γ,showing potential antidiabetic activity.The study can provide reference for further research of chemical ingredients for the treatment of type 2 diabetes.

Texto completo: DisponíveL Índice: WPRIM (Pacífico Ocidental) Tipo de estudo: Estudo diagnóstico / Estudo de rastreamento Idioma: Chinês Revista: China Pharmacy Ano de publicação: 2018 Tipo de documento: Artigo

Similares

MEDLINE

...
LILACS

LIS

Texto completo: DisponíveL Índice: WPRIM (Pacífico Ocidental) Tipo de estudo: Estudo diagnóstico / Estudo de rastreamento Idioma: Chinês Revista: China Pharmacy Ano de publicação: 2018 Tipo de documento: Artigo